Drug Profile
Research programme: personalised targeted immunotherapy - BriaCell Therapeutics
Alternative Names: Off-the-Shelf Personalised ImmunotherapyLatest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator BriaCell Therapeutics Corp
- Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Cell replacements; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for research development in Breast-cancer in USA (Parenteral)
- 10 Nov 2020 BriaCell Therapeutics and the National Cancer Institute agree to co-develop Bria-OTS™ for Cancer
- 21 Jun 2018 Research programme: personalised targeted immunotherapy - BriaCell Therapeutics is available for licensing as of 21 Jun 2018. http://briacell.com/